CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project seeks to create a new immune-cell based treatment for Multiple Myeloma by using ultrasmall macromolecules for enhanced imaging and tracking of immune cells. The goal is to improve personalized treatment strategies and patient outcomes in cancer therapy.
Recent studies on the developments of immune mobilizing monoclonal T-cell receptors against cancer (ImmTAC), bispecific T-cell receptors (TCR) engagers, and chimeric antigen receptor (CAR) cell-based therapies, have highlighted their potential to treat Multiple Myeloma (MM).
These treatments, however, are expensive.
The manufacturing processes that are employed for their generation are lengthy, and their commercial scale production is reliant on a multitude of equipment and operators that cannot…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
GCS INSTITUT DE CANCEROLOGIE STRASBOURG EUROPE
France, STRASBOURG
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
